{"id":"vaxigrip-tetra","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It contains inactivated viruses of four different influenza strains, which stimulate the body's immune system to produce antibodies against these strains. This provides immunity against seasonal influenza A and B viruses.","oneSentence":"Vaxigrip tetra is a quadrivalent inactivated influenza vaccine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:31.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in individuals 6 months of age and older"}]},"trialDetails":[{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT06716567","phase":"PHASE4","title":"Maternal Determinants of Immunity to Influenza","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2020-11-16","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Influenza","enrollment":109},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT05129436","phase":"","title":"Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-10-10","conditions":"Seasonal Influenza Vaccination","enrollment":20},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT02831608","phase":"PHASE4","title":"Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis","status":"COMPLETED","sponsor":"Ole Frobert, MD, PhD","startDate":"2016-10","conditions":"Myocardial Infarction, Influenza, Human, Influenza Vaccines","enrollment":2571},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vaxigrip tetra","genericName":"Vaxigrip tetra","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Biologic","firstApprovalDate":"","aiSummary":"Vaxigrip Tetra is a tetravalent influenza vaccine, which means it protects against four different strains of the influenza virus. It is classified as a small molecule, according to ChEMBL, and has been studied in clinical trials for its effectiveness against influenza and SARS-CoV-2 infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}